Latest ASX Announcements

Dimerix Phase 2a Subgroup Analysis Results

Dimerix Presents Detailed Subgroup Analysis from DMX-200 Phase 2a trial in Chronic Kidney Disease Showing Compelling Efficacy Signals in Diabetic Nephropathy Patients

  • Detailed data from Dimerix’s DMX-200 Phase 2a trial in Chronic Kidney Disease (CKD) presented at American Society of Nephrology’s (ASN) Annual Kidney Week conference in New Orleans this week
  • Post hoc, detailed data […]
By | 2017-11-02T06:46:11+00:00 November 2nd, 2017|Latest ASX Announcements|

Dimerix receives ethics committee approval for pharmacokinetic trial of new extended release formulation

Dimerix Limited (ASX: DXB), is pleased to announce that it has received ethics committee approval for a study in healthy volunteers to determine the pharmacokinetic properties of the novel extended release propagermanium tablet to be used in the Company’s DMX-200 Phase 2b trial in Chronic Kidney Disease.

Read the full release […]

By | 2017-10-24T06:43:29+00:00 October 24th, 2017|Latest ASX Announcements|

ASX Announcement – Dimerix appoints Medical Advisory Board

We are very pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program.

The Medical Advisory Board will provide clinical and strategic input into the Company’s lead program, DMX-200 in Chronic Kidney Disease and will provide guidance to the Company as it shapes and progresses its DMX-200 […]

By | 2017-10-18T11:07:50+00:00 October 18th, 2017|Latest ASX Announcements|